Forest Lab Settles Bystolic Patent Row With Generic Drugmaker

Law360, New York (October 26, 2012, 4:31 PM EDT) -- Pharmaceutical company Forest Laboratories Inc. said Friday it had agreed to drop patent infringement claims against generic drugmaker Hetero Labs Ltd. over the beta-blocker Bystolic after the two reached a licensing agreement for the drug.

Forest said it will give Hetero a license that allows the company to release a generic version of nebivolol — the active ingredient in Bystolic — when the U.S. Food and Drug Administration approves the Hetero's abbreviated new drug application or three months prior to the expiration of Forest's patent, whichever...
To view the full article, register now.